Skip to main content
. 2014 Apr 21;9(4):e95787. doi: 10.1371/journal.pone.0095787

Figure 3. Activation of Jurkat/FcγR/NFAT-Luc cells by EGFR-bound cetuximab and panitumumab.

Figure 3

A431 and Jurkat/FcγR/NFAT-Luc cells were co-cultured in the presence of serially diluted cetuximab (IgG1 subclass) or panitumumab (IgG2 subclass). The luciferase activity (i.e., the fold increase compared to the control sample without mAbs) is represented on the graphs. The assays were performed in triplicate, and the data are the mean ± SEM. Panitumumab activated Jurkat/FcγRIIa/NFAT-Luc cells more strongly than cetuximab (p<0.0001, Graphpad Prism Software).